Impact News +++ Raumfahrt: OHB kündigt Aktienplatzierung und Teilausstieg von KKR an (Handelsblatt) +++ OHB Aktie +4,59%

CERVOMED Aktie

>CERVOMED Aktienkurs

2.08 EUR -2.8% (TradegateBSX)

Ask: 2.18 EUR / 1387 Stück

Bid: 2.08 EUR / 1458 Stück

Tagesumsatz: 12 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

CERVOMED Aktie über LYNX handeln

Intraday

1 Jahr

>CERVOMED Performance

1 Woche: -15,5%

1 Monat: -33,6%

3 Monate: -43,7%

6 Monate: -70,2%

1 Jahr: -67,6%

laufendes Jahr: -68,2%

>CERVOMED Aktie

Name:

CERVOMED INC. DL-,001

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US15713L1098 / A3ES01

Symbol/ Ticker:

DP8 (Frankfurt) / CRVO (NASDAQ)

Kürzel:

FRA:DP8, ETR:DP8, DP8:GR, NASDAQ:CRVO

Index:

Webseite:

https://www.cervomed.com/

Profil:

CervoMed Inc. is a biotechnology company focused on developing treatments for neurodegenerative diseases. With a commitment to improving patient outcomes, the company engages in the research and development of innovative therapies that target underly..
>Volltext..

Marktkapitalisierung:

19.61 Mio. EUR

Unternehmenswert:

8.42 Mio. EUR

Umsatz:

1.81 Mio. EUR

EBITDA:

-26.89 Mio. EUR

Nettogewinn:

-25.97 Mio. EUR

Gewinn je Aktie:

-2.83 EUR

Schulden:

Liquide Mittel:

6.87 Mio. EUR

Operativer Cashflow:

-23.84 Mio. EUR

Bargeldquote:

2.87

Umsatzwachstum:

-78.99%

Gewinnwachstum:

-50.64%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

CERVOMED

Letzte Datenerhebung:

15.06.26

>CERVOMED Kennzahlen

Aktien/ Unternehmen:

Aktien: 9.26 Mio. St.

Frei handelbar: 51.8%

Leerverk. Aktien: 2.84%

Rückkaufquote: -20.29%

Mitarbeiter: 15

Umsatz/Mitarb.: 0.23 Mio. EUR

Analysten:

Analystenrating: Strong buy

Kursziel: 746.69%

Bewertung:

KGV: -

KGV lG: -

KUV: 10.21

KBV: 2.08

PEG-Ratio: -0.01

EV/EBITDA: -

Rentabilität:

Bruttomarge: -

Gewinnmarge: -1437.83%

Operative Marge: -1488.86%

Managementeffizenz:

Gesamtkaprendite: -111.89%

Eigenkaprendite: -132.76%

>CERVOMED Peer Group

Gesundheit, Parkinson- Behandlung, Neurologische Erkrankungen/ Schlaganfälle, Demenz/ Alzheimer- Behandlung

>CERVOMED Chart & Kurs - NASDAQ

>CERVOMED News

12.06.26 - 13:33

CervoMed to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit (GlobeNewswire EN)

BOSTON, June 12, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today announced that Company management will participate in a fireside chat and one-on-one investor meetings at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit, being held virtually on Monday, June 15, 2026....

10.06.26 - 15:01	CervoMed-Aktie fällt um 15 % nach Ankündigung einer Finanzierung über 10,5 Mio. US-Dollar (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

10.06.26 - 13:33	CervoMed Announces Private Placement Financing and Plan to Focus on Strategic Partnering to Advance Neflamapimod into Phase 3 for Dementia with Lewy Bodies (GlobeNewswire EN)
	Additional funding will extend anticipated runway into second quarter of 2027...

18.05.26 - 13:45	CervoMed reports Q1 results (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

18.05.26 - 13:33	CervoMed Reports First Quarter 2026 Financial Results and Provides Corporate Updates (GlobeNewswire EN)
	Continued progress towards initiating planned Phase 3 trial evaluating neflamapimod in patients with dementia with Lewy bodies in second half of 2026, subject to financing...

22.04.26 - 13:33	CervoMed Announces New Data at the 2026 AAN Annual Meeting that Demonstrated Neflamapimod Increased Basal Forebrain Volume and Functional Connectivity in Dementia with Lewy Bodies (GlobeNewswire EN)
	Results consistent with pre-clinical studies demonstrating that, in the early stages of the neurodegenerative process, disease progression in the basal forebrain is reversible...

07.04.26 - 13:33	CervoMed to Provide Neflamapimod Clinical Program Update and Participate in a Panel on Biomarkers at 2026 Lewy Body Dementia Association Annual Meeting (GlobeNewswire EN)
	Update will include new MRI analyses from the Phase 2b RewinD-LB clinical trial, status of global regulatory discussions, and finalized Phase 3 trial design...

19.03.26 - 12:33	CervoMed Announces New Data at the AD/PD™ 2026 Scientific Conference that Reinforce Neflamapimod′s Positive Effects in Dementia with Lewy Bodies (DLB) in Patients without Alzheimer′s Disease Co-Pathology (GlobeNewswire EN)
	New analyses show DLB patients with lower plasma pTau181 levels — indicating an earlier stage of disease and absence of Alzheimer's disease (AD) co-pathology — experienced greater clinical benefit with neflamapimod in Phase 2b clinical trial...

17.03.26 - 12:45	CervoMed reports FY results (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

17.03.26 - 12:33	CervoMed Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates (GlobeNewswire EN)
	Reported positive Phase 2b RewinD-LB clinical data at CTAD 2025; additional analyses to be presented at AD/PD 2026...

14.03.26 - 00:45	CervoMed Inc. (CRVO) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
	CERVOMED INC (CRVO) delivered earnings and revenue surprises of -10.93% and -98.06%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?...

05.03.26 - 13:33	CervoMed to Participate in Upcoming Investor Conferences (GlobeNewswire EN)
	BOSTON, March 05, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders, today announced that Company management will participate in the following investor conferences during the month of March:...

04.03.26 - 13:33	CervoMed Announces Selection of Formulation and Dosing Regimen for Planned Phase 3 Trial in Patients with Dementia with Lewy Bodies (GlobeNewswire EN)
	CervoMed Announces Selection of Formulation and Dosing Regimen for Planned Phase 3 Trial in Patients with Dementia with Lewy Bodies...

18.02.26 - 12:03	CervoMed′s neflamapimod elected for inclusion in UK EXPERTS-ALS platform designed to prioritize promising treatments for Amyotrophic Lateral Sclerosis (GlobeNewswire EN)
	CervoMed's neflamapimod has been selected for the U.K.'s EXPERTS-ALS platform to rapidly evaluate it in ALS...

04.12.25 - 23:24	Vielversprechende Studiendaten zu Demenzmittel beflügeln CervoMed-Aktie (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

04.12.25 - 23:03	CervoMed Announces Late-Breaking Data at the 18th CTAD Conference Demonstrating Neflamapimod Significantly Slows Clinical Progression in Dementia with Lewy Bodies (GlobeNewswire EN)
	Phase 2b trial showed significant improvements on primary and key secondary outcomes measures, most prominently in patients without AD co-pathology...

02.12.25 - 13:03	CervoMed Presents New Plasma Biomarker Data That Indicates Neflamapimod Broadly Improves Neuroinflammation and Neurodegeneration in Dementia with Lewy Bodies (DLB) (GlobeNewswire EN)
	1st of two presentations with results from Phase 2b study of neflamapimod at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference...

24.11.25 - 13:03	CervoMed to Share New Data on Neflamapimod as a Treatment for Dementia with Lewy Bodies at the 18th Clinical Trials on Alzheimer′s Disease (CTAD) Conference (GlobeNewswire EN)
	Late-breaking oral presentation by a leading global authority in Dementia with Lewy bodies (DLB) to highlight updated data from Phase 2b study on neflamapimod treatment for DLB...

19.11.25 - 18:02	Insiderhandel: CFO, GC & Secretary kauft Aktien von CervoMed im Wert von 8450 USD (Insiderkauf)
	Elder, William Robert - Vorstand - Tag der Transaktion: 2025-11-17...

19.11.25 - 18:02	Insiderhandel: Chief Commercial and Business kauft Aktien von CervoMed im Wert von 29505 USD (Insiderkauf)
	Winton, Matthew - Vorstand - Tag der Transaktion: 2025-11-17...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Schlagworte sind Kommandos der Dummheit. - Hans Lohberger

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram